Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes
Get Live Data
131.60    -2.60 (-1.94%)
Bid:
130.40
Ask:
131.00
Spread: 0.60 (0.46%)
Market Cap: £320.34m
PRTC Live PriceLast checked at - London Stock Exchange

Intraday PureTech Share Chart

Holding(s) in Company

8 May 2026 07:00

RNS Number : 5074D
PureTech Health PLC
08 May 2026
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BY2Z0H74

Issuer Name

PURETECH HEALTH PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Briarwood Chase Management LLC

City of registered office (if applicable)

New York

Country of registered office (if applicable)

USA

4. Details of the shareholder

Name

City of registered office

Country of registered office

Morgan Stanley & Co., LLC

New York

USA

5. Date on which the threshold was crossed or reached

06-May-2026

6. Date on which Issuer notified

07-May-2026

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

5.093400

0.000000

5.093400

12398267

Position of previous notification (if applicable)

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BY2Z0H74

12398267

5.093400

Sub Total 8.A

12398267

5.093400%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

 

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Aalap Mahadevia

5.093400

5.093400%

Briarwood Chase Management LLC

5.093400

5.093400%

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

07-May-2026

13. Place Of Completion

New York, NY USA

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLARMBTMTBMTLF
Date   Source Headline
20th Feb 20237:00 amRNSTransaction in Own Shares
17th Feb 20235:00 pmRNSDirector/PDMR Shareholding
17th Feb 20237:00 amRNSTransaction in Own Shares
16th Feb 20237:00 amRNSTransaction in Own Shares
15th Feb 20237:00 amRNSTransaction in Own Shares
14th Feb 202312:00 pmRNSPRTC Plans Ph2a trials w/ LYT-300 in PPD/Anxiety
14th Feb 20237:00 amRNSTransaction in Own Shares
13th Feb 20237:00 amRNSTransaction in Own Shares
10th Feb 20237:00 amRNSTransaction in Own Shares
9th Feb 20237:00 amRNSTransaction in Own Shares
8th Feb 20237:00 amRNSTransaction in Own Shares
7th Feb 20237:00 amRNSTransaction in Own Shares
6th Feb 20237:00 amRNSTransaction in Own Shares
3rd Feb 20237:00 amRNSTransaction in Own Shares
2nd Feb 20237:00 amRNSTransaction in Own Shares
1st Feb 202312:00 pmRNSPureTech to Present at SVB Global Biopharma Conf.
1st Feb 20237:00 amRNSTotal Voting Rights
1st Feb 20237:00 amRNSTransaction in Own Shares
31st Jan 20237:00 amRNSTransaction in Own Shares
30th Jan 20237:00 amRNSTransaction in Own Shares
27th Jan 20237:00 amRNSTransaction in Own Shares
25th Jan 20237:00 amRNSTransaction in Own Shares
6th Jan 20237:00 amRNSAKLI Positive ADHD Pivotal Data in Kids 13-17 yrs
22nd Dec 20227:00 amRNSPRTC Provides Recap Ahead of Catalyst-Rich 2023
19th Dec 202212:00 pmRNSLYT-300 Shows Proof of Principle in Clinical Trial
13th Dec 202212:00 pmRNSPureTech to Present at J.P. Morgan HC Conference
12th Dec 20222:00 pmRNSPRTC Leukemia Data at ASH & Begins AML Trial
9th Dec 202212:00 pmRNSSonde Gets $19M+ for Voice-Based Health Monitoring
7th Dec 20222:13 pmRNSVor Announces AML Clinical Data + Raises $115M
6th Dec 20226:30 pmRNSDirector/PDMR Shareholding
1st Dec 20227:00 amRNSTotal Voting Rights
30th Nov 202212:00 pmRNSPRTC's New Candidate: Oral CBD for Epilepsy/CNS
22nd Nov 20227:00 amRNSTransaction in Own Shares
21st Nov 20227:00 amRNSTransaction in Own Shares
18th Nov 20227:00 amRNSTransaction in Own Shares
17th Nov 202212:00 pmRNSPRTC Presents at Two Upcoming Investor Conferences
17th Nov 20227:00 amRNSTransaction in Own Shares
16th Nov 20227:00 amRNSTransaction in Own Shares
15th Nov 20227:00 amRNSTransaction in Own Shares
14th Nov 20227:00 amRNSTransaction in Own Shares
11th Nov 20227:00 amRNSTransaction in Own Shares
10th Nov 20225:00 pmRNSDirector Declaration
10th Nov 20227:00 amRNSTransaction in Own Shares
9th Nov 202212:00 pmRNSPRTC to Present at Jefferies Healthcare Conference
9th Nov 20227:00 amRNSTransaction in Own Shares
8th Nov 20227:00 amRNSTransaction in Own Shares
7th Nov 20227:00 amRNSTransaction in Own Shares
4th Nov 20227:00 amRNSTransaction in Own Shares
3rd Nov 20227:00 amRNSTransaction in Own Shares
2nd Nov 202211:35 amRNSGelesis Presents New Data at ObesityWeek 2022

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.